Walvax Biotechnology Co Ltd. Stock Analysis 300142.SZ

Walvax Biotechnology Co., Ltd. engages in the research, development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,981 full-time employees. The company went IPO on 2010-11-12. The firm operates through Production segment, research and development segment, Industrial Investment segment, and Sales segment. The firm's products include the 13-valent pneumococcal conjugate vaccine (vial and pre-filled syringe), bivalent human papillomavirus (HPV) vaccine (vial and pre-filled syringe), 23-valent pneumococcal polysaccharide vaccine (vial and pre-filled syringe), Haemophilus influenzae type b conjugate vaccine (vial and pre-filled syringe), meningococcal polysaccharide conjugate vaccine for groups A and C (vial and pre-filled syringe), meningococcal polysaccharide vaccine for groups ACYW135 (vial and pre-filled syringe), meningococcal polysaccharide vaccine for groups A and C (vial), and adsorbed acellular pertussis, diphtheria, and tetanus combined vaccine (vial).